drugset / Trial / NCT00409214
Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The pupose of this study is to demonstrate the safety of the Litx™ therapy and confirm the zone of tumor destruction with escalated light doses following intraoperative treatment of primary or recurrent glioma.
Timeline
- Start
- 2006-11
- Primary completion
- 2008-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LS11 | Other / unclassified | 1 mg/kg | Intravenous |